S. Bazarbashi

Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer

BackgroundEarlier studies that established weekly dosing of cetuximab did not reach a maximum-tolerated dose. Subsequent pharmacokinetic studies showed equal efficacy and toxicity for the...

K. Alshammari ;

N. Alagel ;

H. Elhariry ;

M. Aseafan ;

B. Alshamsan ;

S. Bazarbashi ;

06/25/2023

Characteristic and clinical outcome of localized gastric cancer; real-world data

BackgroundGastric/gastroesophageal junction (GEJ) cancers have a poor prognosis even when present in earlier stages. Different treatment approaches have been studied to improve its outcom...

A. Aljuhani ;

M. Aseafan ;

A. Sheikh ;

A. Alhanash ;

B. Alshamsan ;

S. Bazarbashi ;

06/25/2023